Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 15/20 | 0.37 |
| ▸ | CCR6 | P51684 | 4/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28395925 | 1.00 | CXCR2 (0.37) | CXCR2CCR6MMP2MMP9 | |
| SCHEMBL17293867 | 1.00 | CXCR2 (0.37) | CXCR2CCR6MMP2MMP9 | |
| SCHEMBL17293817 | 0.97 | CXCR2 (0.37) | CXCR2MMP2MMP9 | |
| SCHEMBL28398961 | 0.97 | CXCR2 (0.37) | CXCR2MMP2MMP9 | |
| SCHEMBL19092295 | 0.97 | CXCR2 (0.37) | CXCR2MMP2MMP9 | |
| SCHEMBL19082711 | 0.97 | CXCR2 (0.37) | CXCR2MMP2MMP9 | |
| SCHEMBL17309606 | 0.84 | CXCR2 (0.48) | CXCR2 | |
| SCHEMBL21119095 | 0.82 | CXCR2 (0.43) | CXCR2CCR6 | |
| SCHEMBL28390701 | 0.82 | CXCR2 (0.43) | CXCR2CCR6 | |
| SCHEMBL17309539 | 0.82 | CXCR2 (0.43) | CXCR2CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885CCR6 18/4885MMP2 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.